This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: pulmonary hypertension

July 2018 Br J Cardiol 2018;25:115–7 doi:10.5837/bjc.2018.018 Online First

A pulmonary triad in a patient with a giant left atrial myxoma

Andrea Calo, Madeleine Openshaw, Timothy J Bowker, Han B Xiao

Abstract

Introduction Myxoma is the most common primary cardiac tumour, found in the left atrium in 75% of cases.1,2 Clinical features range from being asymptomatic to symptoms of mitral stenosis, embolisation and systemic illness.3-5 Pulmonary complications, including pulmonary hypertension,4,6,7 pulmonary infarction8 and lymphadenopathy,9 though uncommon, have been reported. Our patient presented with a pulmonary triad of all the complications mentioned above and all of them resolved immediately following successful excision of the tumour. We hope to report this case for educational and clinical purposes, due to the unusual combination of pulmonary

| Full text

October 2016 Online First

Pulmonary hypertension news from ESC and ERS

Logan Thirugnanasothy

Abstract

PH update from ERS The 2015 ESC/ERS guidelines for the diagnosis and treatment of PH Updated collaborative guidelines from the ERS and ESC on the diagnosis and management of pulmonary hypertension (PH) were presented at the ERS by Professor Marc Humbert (chairperson of the ERS taskforce). PH diseases continue to be classified into one of five groups and its haemodynamic definition remains unchanged, with a mean pulmonary artery pressure ≥ 25 mmHg at right heart catheterisation. Right heart catheterisation There is a high prevalence of left heart disease in the PH population. As the pulmonary arterial wedge pressure (PAWP) may be normal in

| Full text

October 2015 Br J Cardiol 2015;22:(4) Online First

Focus on pulmonary hypertension

BJCardio Staff

Abstract

(more…)

| Full text
Pulmonary hypertension in UK clinical practice: an update

May 2015 Br J Cardiol 2015;22(suppl 1):S2–S15 doi:10.5837/bjc.2015.s01

Pulmonary hypertension in UK clinical practice: an update

Dr J Simon R Gibbs, Dr J Gerry Coghlan, Dr David G Kiely, Dr S John Wort

Abstract

(more…)

| Full text

March 2014 Br J Cardiol 2014;21:16

In brief

BJCardio Staff

Abstract

New drugs for diabetes A new DPP-4i for the management of type 2 diabetes, alogliptin (Vipidia®) has been launched by Takeda in the UK following data from EXAMINE, an outcome trial conducted in high risk acute coronary syndrome patients (see Br J Cardiol 2013;4:131) where the drug significantly reduced glucose levels and also demonstrated cardiovascular safety. Alogliptin and the fixed-dose combination product alogliptin and metformin (Vipdomet®) are now available in the UK. Alogliptin is licensed for the treatment of type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lo

| Full text

November 2006 Br J Cardiol 2006;13:419-24

Eisenmenger syndrome – conventional management and new therapeutic prospects

Anita Dumitrescu, Kevin P Walsh

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now